VTD-melphalan is well tolerated and results in very high rates of stringent CR and MRD-negative status in multiple myeloma

Kalyan Nadiminti1 Division of Hematology/Oncology;2 Holden Comprehensive Cancer Center

Kamal Kant Singh Abbi2 Holden Comprehensive Cancer Center;3 Department of Internal Medicine, Blood and Marrow Transplantation, University of Iowa Hospitals and Clinics, Iowa City, IA, USA

Sarah L Mott2 Holden Comprehensive Cancer Center

Lindsay Dozeman2 Holden Comprehensive Cancer Center

Annick Tricot2 Holden Comprehensive Cancer Center

Allyson Schultz2 Holden Comprehensive Cancer Center

Sonya Behrends2 Holden Comprehensive Cancer Center;3 Department of Internal Medicine, Blood and Marrow Transplantation, University of Iowa Hospitals and Clinics, Iowa City, IA, USA

Fenghuang Zhan2 Holden Comprehensive Cancer Center;3 Department of Internal Medicine, Blood and Marrow Transplantation, University of Iowa Hospitals and Clinics, Iowa City, IA, USA

Guido Tricot2 Holden Comprehensive Cancer Center;3 Department of Internal Medicine, Blood and Marrow Transplantation, University of Iowa Hospitals and Clinics, Iowa City, IA, USACorrespondence[email protected]

show all

Citations (3)

Keep up to date with the latest research on this topic with citation updates for this article.

VTD-melphalan is well tolerated and results in very high rates of stringent CR and MRD-negative status in multiple myeloma

Articles from other publishers (3)

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

VTD-melphalan is well tolerated and results in very high rates of stringent CR and MRD-negative status in multiple myeloma

Citations (3)

Articles from other publishers (3)

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date